Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
Identifieur interne : 001132 ( Main/Corpus ); précédent : 001131; suivant : 001133Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
Auteurs : Azita Hajhossein Talasaz ; Hessam Kakavand ; Benjamin Van Tassell ; Maryam Aghakouchakzadeh ; Parham Sadeghipour ; Steven Dunn ; Babak GeraielySource :
- Cardiovascular drugs and therapy [ 1573-7241 ] ; 2021.
English descriptors
- KwdEn :
- Antiviral Agents (classification), Antiviral Agents (pharmacology), COVID-19 (complications), COVID-19 (drug therapy), COVID-19 (epidemiology), COVID-19 (physiopathology), Cardiovascular Diseases (epidemiology), Cardiovascular Diseases (therapy), Comorbidity (MeSH), Humans (MeSH), Prognosis (MeSH), Risk Assessment (MeSH), SARS-CoV-2 (MeSH).
- MESH :
- chemical , classification : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- complications : COVID-19.
- drug therapy : COVID-19.
- epidemiology : COVID-19, Cardiovascular Diseases.
- physiopathology : COVID-19.
- therapy : Cardiovascular Diseases.
- Comorbidity, Humans, Prognosis, Risk Assessment, SARS-CoV-2.
Abstract
Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.
DOI: 10.1007/s10557-020-07037-2
PubMed: 32671601
PubMed Central: PMC7360896
Links to Exploration step
pubmed:32671601Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.</title><author><name sortKey="Talasaz, Azita Hajhossein" sort="Talasaz, Azita Hajhossein" uniqKey="Talasaz A" first="Azita Hajhossein" last="Talasaz">Azita Hajhossein Talasaz</name><affiliation><nlm:affiliation>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Kakavand, Hessam" sort="Kakavand, Hessam" uniqKey="Kakavand H" first="Hessam" last="Kakavand">Hessam Kakavand</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Van Tassell, Benjamin" sort="Van Tassell, Benjamin" uniqKey="Van Tassell B" first="Benjamin" last="Van Tassell">Benjamin Van Tassell</name><affiliation><nlm:affiliation>Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aghakouchakzadeh, Maryam" sort="Aghakouchakzadeh, Maryam" uniqKey="Aghakouchakzadeh M" first="Maryam" last="Aghakouchakzadeh">Maryam Aghakouchakzadeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Sadeghipour, Parham" sort="Sadeghipour, Parham" uniqKey="Sadeghipour P" first="Parham" last="Sadeghipour">Parham Sadeghipour</name><affiliation><nlm:affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Dunn, Steven" sort="Dunn, Steven" uniqKey="Dunn S" first="Steven" last="Dunn">Steven Dunn</name><affiliation><nlm:affiliation>University of Virginia Health System, Charlottesville, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Geraiely, Babak" sort="Geraiely, Babak" uniqKey="Geraiely B" first="Babak" last="Geraiely">Babak Geraiely</name><affiliation><nlm:affiliation>Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32671601</idno><idno type="pmid">32671601</idno><idno type="doi">10.1007/s10557-020-07037-2</idno><idno type="pmc">PMC7360896</idno><idno type="wicri:Area/Main/Corpus">001132</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.</title><author><name sortKey="Talasaz, Azita Hajhossein" sort="Talasaz, Azita Hajhossein" uniqKey="Talasaz A" first="Azita Hajhossein" last="Talasaz">Azita Hajhossein Talasaz</name><affiliation><nlm:affiliation>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</nlm:affiliation></affiliation></author><author><name sortKey="Kakavand, Hessam" sort="Kakavand, Hessam" uniqKey="Kakavand H" first="Hessam" last="Kakavand">Hessam Kakavand</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Van Tassell, Benjamin" sort="Van Tassell, Benjamin" uniqKey="Van Tassell B" first="Benjamin" last="Van Tassell">Benjamin Van Tassell</name><affiliation><nlm:affiliation>Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation><affiliation><nlm:affiliation>Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aghakouchakzadeh, Maryam" sort="Aghakouchakzadeh, Maryam" uniqKey="Aghakouchakzadeh M" first="Maryam" last="Aghakouchakzadeh">Maryam Aghakouchakzadeh</name><affiliation><nlm:affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Sadeghipour, Parham" sort="Sadeghipour, Parham" uniqKey="Sadeghipour P" first="Parham" last="Sadeghipour">Parham Sadeghipour</name><affiliation><nlm:affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author><author><name sortKey="Dunn, Steven" sort="Dunn, Steven" uniqKey="Dunn S" first="Steven" last="Dunn">Steven Dunn</name><affiliation><nlm:affiliation>University of Virginia Health System, Charlottesville, VA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Geraiely, Babak" sort="Geraiely, Babak" uniqKey="Geraiely B" first="Babak" last="Geraiely">Babak Geraiely</name><affiliation><nlm:affiliation>Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Cardiovascular drugs and therapy</title><idno type="eISSN">1573-7241</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (classification)</term><term>Antiviral Agents (pharmacology)</term><term>COVID-19 (complications)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (epidemiology)</term><term>COVID-19 (physiopathology)</term><term>Cardiovascular Diseases (epidemiology)</term><term>Cardiovascular Diseases (therapy)</term><term>Comorbidity (MeSH)</term><term>Humans (MeSH)</term><term>Prognosis (MeSH)</term><term>Risk Assessment (MeSH)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Comorbidity</term><term>Humans</term><term>Prognosis</term><term>Risk Assessment</term><term>SARS-CoV-2</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32671601</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-7241</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Cardiovascular drugs and therapy</Title><ISOAbbreviation>Cardiovasc Drugs Ther</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.</ArticleTitle><Pagination><MedlinePgn>249-259</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10557-020-07037-2</ELocationID><Abstract><AbstractText>Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared "pandemic" by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Talasaz</LastName><ForeName>Azita Hajhossein</ForeName><Initials>AH</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-1839-3685</Identifier><AffiliationInfo><Affiliation>Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. a-talasaz@tums.ac.ir.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kakavand</LastName><ForeName>Hessam</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Tassell</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacotherapy and Outcome Science, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, School of Pharmacy, Virginia Commonwealth University, Richmond, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghakouchakzadeh</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadeghipour</LastName><ForeName>Parham</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunn</LastName><ForeName>Steven</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Virginia Health System, Charlottesville, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geraiely</LastName><ForeName>Babak</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cardiovasc Drugs Ther</MedlineTA><NlmUniqueID>8712220</NlmUniqueID><ISSNLinking>0920-3206</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cardiovascular</Keyword><Keyword MajorTopicYN="N">Drug–drug interactions</Keyword><Keyword MajorTopicYN="N">Pharmacotherapy</Keyword><Keyword MajorTopicYN="N">SARS-Cov2</Keyword><Keyword MajorTopicYN="N">Venous thromboembolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32671601</ArticleId><ArticleId IdType="doi">10.1007/s10557-020-07037-2</ArticleId><ArticleId IdType="pii">10.1007/s10557-020-07037-2</ArticleId><ArticleId IdType="pmc">PMC7360896</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>https://www.who.int/dg/speeches/detail/whodirector-general-s-opening-remarks-at-the-media-briefing-on-covid-19%2D%2D-11-march-2020 . Accessed 12 March 2020.</Citation></Reference><Reference><Citation>Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multi-organ response. Curr Probl Cardiol. 2020;45(8):100618.</Citation><ArticleIdList><ArticleId IdType="pubmed">32439197</ArticleId><ArticleId IdType="pmcid">32439197</ArticleId></ArticleIdList></Reference><Reference><Citation>W-j G, Ni Z-y HY, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–20.</Citation></Reference><Reference><Citation>Xiong T-Y, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798–800.</Citation><ArticleIdList><ArticleId IdType="pubmed">32186331</ArticleId><ArticleId IdType="pmcid">32186331</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebinger JE, Shah PK. Declining admissions for acute cardiovascular illness: the Covid-19 paradox. J Am Coll Cardiol. 2020;1097(20):35394–8.</Citation></Reference><Reference><Citation>Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: the fragile balance between infections and autoimmunity. Int J Mol Sci. 2020;21(9):3330.</Citation><ArticleIdList><ArticleId IdType="pmcid">7247555</ArticleId></ArticleIdList></Reference><Reference><Citation>Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020.</Citation></Reference><Reference><Citation>Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv. 2020.</Citation></Reference><Reference><Citation>Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020.</Citation></Reference><Reference><Citation>Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–90.</Citation></Reference><Reference><Citation>Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharm T. 2007;50(2):112–9.</Citation></Reference><Reference><Citation>Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol-Lung C. 2018;314(1):17–31.</Citation></Reference><Reference><Citation>Zheng Y-Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">32139904</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–100.</Citation><ArticleIdList><ArticleId IdType="pubmed">32227090</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;S0033–0620(20):30055–4.</Citation></Reference><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China The Lancet. 2020;395(10223):497–506.</Citation></Reference><Reference><Citation>Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. JAMA Cardiol: China; 2020.</Citation></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan. China JAMA. 2020;323(11):1061–9.</Citation></Reference><Reference><Citation>https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance . Last updated on 10 June 2020.</Citation></Reference><Reference><Citation>Welt FG, Shah PB, Aronow HD, et al. Catheterization laboratory considerations during the coronavirus (COVID-19) pandemic: from ACC’s interventional council and SCAI. J Am Coll Cardiol. 2020;75(18):2372–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">32199938</ArticleId><ArticleId IdType="pmcid">7270593</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Kardiol Pol. 2018;76(2):229.</Citation><ArticleIdList><ArticleId IdType="pubmed">29457615</ArticleId></ArticleIdList></Reference><Reference><Citation>Berwanger O, Lopes RD, Moia DD, et al. Ticagrelor versus clopidogrel in patients with STEMI treated with fibrinolysis: TREAT trial. J Am Coll Cardiol. 2019;73(22):2819–28.</Citation><ArticleIdList><ArticleId IdType="pubmed">30898608</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. 2020;S0735–1097(20):35008–7.</Citation></Reference><Reference><Citation>Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixon DL, Van Tassell BW, Vecchié A, et al. Cardiovascular considerations in treating patients with coronavirus disease 2019 (COVID-19). J Cardiovasc Pharmacol. 2020;75(5):359–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">32282502</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):3168–209.</Citation><ArticleIdList><ArticleId IdType="pubmed">30423391</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">30580575</ArticleId></ArticleIdList></Reference><Reference><Citation>Giguère P, Nhean S, Tseng AL, Hughes CA, Angel JB. Getting to the heart of the matter: a review of drug interactions between HIV antiretrovirals and cardiology medications. Can J Cardiol. 2019;35(3):326–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">30825953</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21.</Citation><ArticleIdList><ArticleId IdType="pubmed">32171062</ArticleId><ArticleId IdType="pmcid">7118626</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11(8):875–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7095783</ArticleId><ArticleId IdType="pmcid">7095783</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020.</Citation></Reference><Reference><Citation>Reynolds HR, Adhikari S, Pulgarin C, et al. Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020.</Citation></Reference><Reference><Citation>Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020.</Citation></Reference><Reference><Citation>Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19. J Card Fail. 2020;26(5):370.</Citation><ArticleIdList><ArticleId IdType="pubmed">32439095</ArticleId><ArticleId IdType="pmcid">7234783</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardiology ESo. Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. ESC. 2020.</Citation></Reference><Reference><Citation>Mehra MR, Ruschitzka F. COVID-19 illness and heart failure: a missing link? JACC Heart Fail. 2020;8(6):512–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">32360242</ArticleId><ArticleId IdType="pmcid">7151428</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong N, Cai J, Zhou Y, Liu J, Li F. End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV. JACC Heart Fail. 2020;S2213–1779(20):30200–6.</Citation></Reference><Reference><Citation>Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636–48.</Citation></Reference><Reference><Citation>Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020.</Citation></Reference><Reference><Citation>Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020.</Citation></Reference><Reference><Citation>Tavazzi G, Pellegrini C, Maurelli M, et al. Myocardial localization of coronavirus in COVID-19 cardiogenic shock. Eur Heart Fail. 2020;22(5):911–5.</Citation></Reference><Reference><Citation>Alhazzani W, Møller MH, Arabi YM, et al. Surviving Sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19). Intensive Care Med. 2020;46:854–87.</Citation><ArticleIdList><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>Poston JT, Patel BK, Davis AM. Management of critically ill adults with COVID-19. JAMA. 2020;323(18):1839–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">32215647</ArticleId></ArticleIdList></Reference><Reference><Citation>Frustaci A, Chimenti C, Calabrese F, Pieroni M, Thiene G, Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation. 2003;107(6):857–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">12591756</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul J-F, Charles P, Richaud C, Caussin C, Diakov C. Myocarditis revealing COVID-19 infection in a young patient. Eur Heart J Cardiovas Imaging. 2020:jeaa107.</Citation></Reference><Reference><Citation>Dabbagh MF, Aurora L, D’Souza P, Weinmann AJ, Bhargava P, Basir MB. Cardiac tamponade secondary to COVID-19. Case Reports: JACC; 2020.</Citation></Reference><Reference><Citation>Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of colchicine vs standard care on cardiac and inflammatory biomarkers and clinical outcomes in patients hospitalized with coronavirus disease 2019: the GRECCO-19 randomized clinical trial. JAMA Netw Open. 2020;3(6):e2013136.</Citation><ArticleIdList><ArticleId IdType="pubmed">32579195</ArticleId><ArticleId IdType="pmcid">7315286</ArticleId></ArticleIdList></Reference><Reference><Citation>Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020;75(18):2352–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">32201335</ArticleId><ArticleId IdType="pmcid">7198856</ArticleId></ArticleIdList></Reference><Reference><Citation>Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020;14(3):247–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">32247212</ArticleId><ArticleId IdType="pmcid">7102662</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh S, Desai R. COVID-19 And New Onset Arrhythmia. Journal of Arrhythmia. 2020:joa3.</Citation></Reference><Reference><Citation>Lazzerini PE, Boutjdir M, Capecchi PL. COVID-19, arrhythmic risk and inflammation: mind the gap! Circulation. 2020.</Citation></Reference><Reference><Citation>Zeitlinger M. Pharmacokinetics-pharmacodynamics of antiviral agents used to treat SARS-CoV-2 and their potential interaction with drugs and other supportive measures: a comprehensive review by the PK/PD of anti-Infectives study Group of the European Society of antimicrobial agents. 2020.</Citation></Reference><Reference><Citation>Giudicessi JR. Urgent guidance for navigating and circumventing the QTc prolonging and Torsadogenic potential of possible pharmacotherapies for COVID-19. Mayo Clin Proc. 2020;6:1213–21.</Citation></Reference><Reference><Citation>Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. 2020;S0140–6736(20):31180–6.</Citation></Reference><Reference><Citation>Tisdale JE, Jaynes HA, Kingery JR, et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Cir Cardiovasc Qual. 2013;6(4):479–87.</Citation></Reference><Reference><Citation>Haugaa KH, Bos JM, Tarrell RF, Morlan BW, Caraballo PJ, Ackerman MJ. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc. 2013;88(4):315–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">23541006</ArticleId></ArticleIdList></Reference><Reference><Citation>Simpson TF, Kovacs RJ, Stecker EC. Ventricular arrhythmia risk due to Hydroxychloroquine-azithromycin treatment for COVID-19. Ame Coll Cardiol. 2020.</Citation></Reference><Reference><Citation>Roden DM, Harrington RA, Poppas A, Russo AM. Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment. Circulation. 2020.</Citation></Reference><Reference><Citation>Sapp JL, Alqarawi W, MacIntyre CJ, et al. Guidance on minimizing risk of drug-induced ventricular arrhythmia during treatment of COVID-19: a statement from the Canadian Heart Rhythm Society. Can J Cardiol. 2020.</Citation></Reference><Reference><Citation>Wu C-I, Postema PG, Arbelo E, et al. SARS-CoV-2, COVID-19 and inherited arrhythmia syndromes. Heart Rhythm. 2020.</Citation></Reference><Reference><Citation>Jeevaratnam K. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety. Eur Heart J Cardiovasc Pharmacother. 2020:pvaa041.</Citation></Reference><Reference><Citation>Vidovich MI. Transient Brugada-like electrocardiographic pattern in a patient with COVID-19. Case Reports: JACC; 2020.</Citation></Reference><Reference><Citation>Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):884–7.</Citation></Reference><Reference><Citation>Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">32339221</ArticleId><ArticleId IdType="pmcid">7273827</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok FA, Kruip MJHA, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">32291094</ArticleId><ArticleId IdType="pmcid">7146714</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17):e38.</Citation><ArticleIdList><ArticleId IdType="pubmed">32268022</ArticleId><ArticleId IdType="pmcid">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowles L, Platton S, Yartey N, et al. Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19. N Engl J Med. 2020.</Citation></Reference><Reference><Citation>Iba T, Levy JH, Warkentin TE, et al. Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation. J Thromb Haemost. 2019;17(11):1989–94.</Citation></Reference><Reference><Citation>Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis. Clin Chim Acta. 2020.</Citation></Reference><Reference><Citation>Liang W, Liang H, Ou L, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020.</Citation></Reference><Reference><Citation>Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18(5):1023–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32338827</ArticleId></ArticleIdList></Reference><Reference><Citation>Poissy J, Goutay J, Caplan M, et al. Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence. Circulation. 2020.</Citation></Reference><Reference><Citation>Obi AT, Barnes GD, Wakefield TW, Eliason JL, Arndt E, Henke PK. Practical diagnosis and treatment of suspected venous thromboembolism during COVID-19 pandemic. J Vasc Surg-Venous L. 2020.</Citation></Reference><Reference><Citation>Bikdeli B, Madhavan MV, Gupta A, et al. Pharmacological agents targeting Thromboinflammation in COVID-19: review and implications for future research. Thromb Haemost. 2020.</Citation></Reference><Reference><Citation>Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858.</Citation><ArticleIdList><ArticleId IdType="pubmed">32227120</ArticleId></ArticleIdList></Reference><Reference><Citation>Obi AT, Tignanelli CJ, Jacobs BN, et al. Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza a H1N1 acute respiratory distress syndrome patients. J Vasc Surg-Venous L. 2019;7(3):317–24.</Citation></Reference><Reference><Citation>Li J, Yang B, Wang H. Low-molecular-weight heparin treatment for acute lung injury/acute respiratory distress syndrome: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2018;11(2):414–22.</Citation></Reference><Reference><Citation>Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020;7(5):e362–e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">32278361</ArticleId><ArticleId IdType="pmcid">7158946</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiggins BS, Dixon DL, Neyens RR, Page RL II, Gluckman TJ. Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week. J Am Coll Cardiol. 2020;75(11):1341–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">32192661</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001132 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001132 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32671601
|texte= Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32671601" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |